Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Alain Le Quellec"'
Autor:
Stanislas Faguer, H. François, Alain Le Quellec, Guillaume Moulis, Laurent Chiche, Alexandre Karras, Philippe Remy, Xavier Mariette, Aurélie Hummel, Evguenia Krastinova, Perrine Jullien, Anne-Laure Fauchais, J.B. Fraison, Véronique Le Guern, Estibaliz Lazaro, R. Mesbah, Magali Jasiek, Noémie Jourde-Chiche, Emmanuelle Dernis, Benjamin Terrier, Sophie Ferlicot, Carole Cordonnier, Philippe Vanhille, Pierre Ronco, Eric Thervet, Raphaèle Seror, Nathalie Costedoat-Chalumeau, Eric Hachulla, Vannary Meas-Yedid, Laurent Daniel
Publikováno v:
Rheumatology
Rheumatology, Oxford University Press (OUP), 2017, 56 (3), pp.362-370. ⟨10.1093/rheumatology/kew376⟩
Rheumatology, 2017, 56 (3), pp.362-370. ⟨10.1093/rheumatology/kew376⟩
ResearcherID
Rheumatology, Oxford University Press (OUP), 2017, 56 (3), pp.362-370. ⟨10.1093/rheumatology/kew376⟩
Rheumatology, 2017, 56 (3), pp.362-370. ⟨10.1093/rheumatology/kew376⟩
ResearcherID
International audience; Objective. Renal involvement is a rare event during primary SS (pSS). We aimed to describe the clinico-biological and histopathological characteristics of pSS-related nephropathy and its response to treatment. Methods. We cond
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6eb5316ac3e077e0c06244350908dd5
https://hal-amu.archives-ouvertes.fr/hal-01791205
https://hal-amu.archives-ouvertes.fr/hal-01791205
Autor:
Bernard Bonnotte, Jean Sibilia, Luc Mouthon, Maxime Samson, Xavier Puéchal, Alain Le Quellec, Thomas Papo, P. Gobert, Mohamed Hamidou, Jean-Robert Harlé, Jean-Christophe Lega, Alfred Mahr, Frederick Vandergheynst, Grégory Pugnet, Eric Hachulla, Pascal Godmer, Loïc Guillevin, Benjamin Terrier, Boris Bienvenu, Alexandre Karras, Pierre Charles
Publikováno v:
La Presse Médicale. 42:1317-1330
Increasing rituximab prescription for ANCA-associated necrotizing vasculitides justifies the publication of recommendations for clinicians. Rituximab is approved in the United States to induce and maintain remission. In Europe, rituximab was recently